Index RUT
P/E -
EPS (ttm) -1.21
Insider Own 26.73%
Shs Outstand 68.63M
Perf Week 4.77%
Market Cap 985.35M
Forward P/E -
EPS next Y -0.44
Insider Trans 7.66%
Shs Float 55.70M
Perf Month -15.57%
Income -78.50M
PEG -
EPS next Q -0.32
Inst Own 47.07%
Short Float 14.50%
Perf Quarter -4.71%
Sales 17.49M
P/S 56.34
EPS this Y 7.07%
Inst Trans -4.06%
Short Ratio 9.55
Perf Half Y 99.08%
Book/sh 0.69
P/B 18.81
EPS next Y 60.75%
ROA -62.36%
Short Interest 8.07M
Perf Year 95.48%
Cash/sh 1.10
P/C 11.78
EPS next 5Y -
ROE -114.01%
52W Range 5.71 - 16.99
Perf YTD 7.73%
Dividend Est. -
P/FCF -
EPS past 5Y 30.44%
ROI -158.09%
52W High -23.72%
Beta 0.26
Dividend TTM -
Quick Ratio 4.85
Sales past 5Y 423.30%
Gross Margin 76.18%
52W Low 126.97%
ATR (14) 0.69
Dividend Ex-Date -
Current Ratio 4.85
EPS Y/Y TTM -73.00%
Oper. Margin -419.62%
RSI (14) 40.78
Volatility 4.44% 5.03%
Employees 136
Debt/Eq 0.07
Sales Y/Y TTM 9.75%
Profit Margin -448.89%
Recom 1.57
Target Price 23.86
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q -314.22%
Payout -
Rel Volume 0.41
Prev Close 13.17
Sales Surprise -4.30%
EPS Surprise -81.66%
Sales Q/Q -15.47%
Earnings Mar 13 BMO
Avg Volume 845.82K
Price 12.96
SMA20 -5.91%
SMA50 -10.04%
SMA200 29.68%
Trades
Volume 159,354
Change -1.59%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-24 Reiterated
Needham
Buy
$18 → $28
Sep-19-22 Resumed
Wedbush
Underperform
$3
Sep-01-22 Downgrade
Wedbush
Neutral → Underperform
$3
Jul-22-22 Initiated
Ladenburg Thalmann
Buy
$15
May-31-22 Initiated
BTIG Research
Buy
$14
May-26-22 Initiated
BofA Securities
Buy
$12
Dec-04-20 Initiated
H.C. Wainwright
Buy
$6
Nov-20-20 Downgrade
Wedbush
Outperform → Neutral
$20 → $4
Nov-08-18 Resumed
Jefferies
Buy
Sep-05-18 Initiated
Wedbush
Outperform
$26
Aug-20-18 Initiated
Needham
Buy
$30
Aug-20-18 Initiated
Jefferies
Buy
$22
Show Previous Ratings
Apr-25-24 10:02AM
Apr-02-24 09:00AM
Apr-01-24 06:00AM
Mar-20-24 01:50AM
01:49AM
02:42PM
Loading…
Mar-16-24 02:42PM
Mar-13-24 10:54PM
(Thomson Reuters StreetEvents) +5.36%
07:31AM
07:10AM
06:00AM
Mar-06-24 06:30AM
Feb-21-24 03:17PM
06:51AM
06:24AM
Jan-30-24 06:30AM
09:55AM
Loading…
Jan-29-24 09:55AM
Jan-25-24 06:25AM
06:00AM
Jan-19-24 06:30AM
Jan-09-24 06:21PM
04:56PM
Jan-08-24 08:22AM
Jan-05-24 06:45AM
Jan-04-24 09:10AM
Jan-02-24 06:45AM
Dec-29-23 06:45AM
Dec-25-23 08:00AM
Dec-22-23 06:35PM
Dec-20-23 04:56PM
Dec-19-23 01:02PM
07:13AM
Loading…
Dec-12-23 07:13AM
Nov-08-23 10:47AM
12:44AM
(Thomson Reuters StreetEvents)
Nov-07-23 07:07AM
06:30AM
Oct-31-23 06:30AM
Oct-02-23 07:00AM
Sep-25-23 04:09PM
Sep-06-23 04:30PM
Aug-13-23 05:22AM
Aug-11-23 12:38AM
(Thomson Reuters StreetEvents) -9.13%
Aug-10-23 07:15AM
06:00AM
Aug-03-23 08:17AM
Jul-27-23 09:13AM
06:00AM
Jul-25-23 02:37PM
(American City Business Journals)
08:25AM
(American City Business Journals)
Jul-24-23 01:46PM
Jun-29-23 11:24AM
Jun-28-23 05:36AM
May-31-23 06:30AM
May-30-23 11:26AM
May-21-23 03:39PM
May-19-23 06:15AM
May-09-23 06:33AM
May-04-23 09:15AM
06:30AM
May-02-23 06:45AM
Apr-27-23 06:45AM
Apr-20-23 04:17AM
Apr-18-23 08:33AM
Apr-11-23 06:45AM
Apr-03-23 06:45AM
Mar-25-23 08:33AM
Mar-20-23 04:10AM
Mar-18-23 08:34AM
Mar-17-23 03:22AM
(Thomson Reuters StreetEvents)
Mar-16-23 07:55AM
06:30AM
Mar-09-23 10:00AM
07:19AM
Feb-17-23 07:33AM
Feb-05-23 08:49PM
(American City Business Journals)
Feb-03-23 05:10AM
Feb-02-23 04:39PM
06:30AM
Jan-09-23 10:01PM
(American City Business Journals)
06:30AM
Dec-30-22 09:40AM
Dec-14-22 09:40AM
Dec-05-22 04:05PM
Dec-01-22 09:55AM
Nov-28-22 09:40AM
Nov-08-22 07:45AM
06:30AM
Nov-02-22 10:15AM
Nov-01-22 06:45AM
Oct-27-22 04:10PM
Oct-26-22 09:40AM
Oct-17-22 06:30AM
Sep-26-22 06:45AM
Sep-10-22 08:24AM
Sep-08-22 11:26AM
Sep-06-22 12:15PM
(American City Business Journals)
Sep-02-22 05:58PM
Aug-31-22 07:46PM
09:55AM
09:40AM
Aug-23-22 03:09PM
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Saggar Rajeev Chief Medical Officer Apr 19 '24 Sale 13.68 1,649 22,558 211,672 Apr 23 05:24 PM JEFFS ROGER Chief Executive Officer Apr 12 '24 Sale 14.58 8,360 121,889 826,985 Apr 16 05:15 PM Kaseta Michael CFO and COO Apr 12 '24 Sale 14.58 3,136 45,723 315,045 Apr 16 05:16 PM Schundler Russell General Counsel Apr 12 '24 Sale 14.58 2,060 30,035 486,027 Apr 16 05:17 PM Moomaw Scott Chief Commercial Officer Apr 12 '24 Sale 14.58 1,585 23,109 151,881 Apr 16 05:16 PM Saggar Rajeev Chief Medical Officer Apr 12 '24 Sale 14.58 1,525 22,234 213,321 Apr 16 05:17 PM Adair Jason Chief Business Officer Apr 12 '24 Sale 14.58 1,189 17,336 111,537 Apr 15 08:31 PM JEFFS ROGER Chief Executive Officer Mar 18 '24 Sale 15.82 28,583 452,183 835,345 Mar 19 09:46 PM Kaseta Michael CFO and COO Mar 18 '24 Sale 15.82 12,166 192,466 318,181 Mar 19 09:47 PM Schundler Russell General Counsel Mar 18 '24 Sale 15.82 8,653 136,890 488,087 Mar 19 09:48 PM Saggar Rajeev Chief Medical Officer Mar 18 '24 Sale 15.82 7,530 119,125 214,846 Mar 19 09:46 PM Moomaw Scott Chief Commercial Officer Mar 18 '24 Sale 15.82 6,108 96,629 153,466 Mar 19 09:47 PM Adair Jason Chief Business Officer Mar 18 '24 Sale 15.81 4,657 73,649 108,640 Mar 19 09:50 PM Moomaw Scott Chief Commercial Officer Feb 29 '24 Sale 14.17 546 7,737 159,574 Mar 04 07:07 PM Adair Jason Chief Business Officer Feb 29 '24 Sale 14.17 455 6,447 97,412 Mar 04 07:05 PM Adair Jason Chief Business Officer Dec 18 '23 Sale 7.70 77 593 54,932 Dec 20 05:20 PM Caligan Partners LP Director Dec 14 '23 Buy 7.16 1,117,318 7,999,997 11,280,945 Dec 14 04:42 PM Manning Paul B Director Dec 14 '23 Buy 7.16 279,330 2,000,003 279,330 Dec 18 05:00 PM JEFFS ROGER Chief Executive Officer Dec 14 '23 Buy 7.16 139,665 1,000,001 640,805 Dec 18 05:02 PM Moomaw Scott Chief Commercial Officer Nov 30 '23 Sale 7.28 542 3,946 106,737 Dec 05 09:18 PM Lippe Robert A Chief Operations Officer Nov 30 '23 Sale 7.28 497 3,618 193,788 Dec 05 09:21 PM Adair Jason Chief Business Officer Nov 30 '23 Sale 7.28 452 3,291 54,478 Dec 05 09:15 PM Adair Jason Chief Business Officer Sep 19 '23 Sale 6.51 75 488 53,637 Sep 20 06:14 PM Moomaw Scott Chief Commercial Officer Aug 31 '23 Sale 6.88 537 3,695 105,404 Sep 05 08:10 PM Lippe Robert A Chief Operations Officer Aug 31 '23 Sale 6.88 505 3,474 192,567 Sep 05 08:11 PM Adair Jason Chief Business Officer Aug 31 '23 Sale 6.88 445 3,062 53,452 Sep 05 08:09 PM Moomaw Scott Chief Commercial Officer May 31 '23 Sale 8.08 651 5,260 102,268 Jun 02 05:05 PM Lippe Robert A Chief Operations Officer May 31 '23 Sale 8.08 597 4,824 189,646 Jun 02 05:03 PM
Index -
P/E -
EPS (ttm) -1.34
Insider Own 31.23%
Shs Outstand 186.96M
Perf Week 9.57%
Market Cap 471.29M
Forward P/E -
EPS next Y -0.48
Insider Trans 0.17%
Shs Float 128.62M
Perf Month -7.35%
Income -111.57M
PEG -
EPS next Q -0.11
Inst Own 62.24%
Short Float 12.49%
Perf Quarter 61.54%
Sales 15.45M
P/S 30.50
EPS this Y 57.71%
Inst Trans -1.76%
Short Ratio 5.67
Perf Half Y 7.69%
Book/sh 0.40
P/B 6.29
EPS next Y -17.13%
ROA -56.40%
Short Interest 16.07M
Perf Year 245.25%
Cash/sh 0.77
P/C 3.26
EPS next 5Y -
ROE -294.04%
52W Range 0.50 - 3.89
Perf YTD 42.37%
Dividend Est. -
P/FCF -
EPS past 5Y -137.69%
ROI -83.01%
52W High -35.22%
Beta 0.35
Dividend TTM -
Quick Ratio 4.06
Sales past 5Y 129.39%
Gross Margin 86.86%
52W Low 404.00%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 4.06
EPS Y/Y TTM 64.68%
Oper. Margin -461.94%
RSI (14) 49.06
Volatility 7.49% 9.15%
Employees 52
Debt/Eq 0.82
Sales Y/Y TTM 517.55%
Profit Margin -722.06%
Recom 1.11
Target Price 6.83
Option/Short Yes / Yes
LT Debt/Eq 0.79
EPS Q/Q 125.84%
Payout -
Rel Volume 0.54
Prev Close 2.42
Sales Surprise 23.41%
EPS Surprise 331.76%
Sales Q/Q 44.04%
Earnings Mar 19 AMC
Avg Volume 2.83M
Price 2.52
SMA20 -3.07%
SMA50 -4.76%
SMA200 18.89%
Trades
Volume 702,202
Change 4.13%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-09-24 Initiated
Piper Sandler
Overweight
$9
Feb-01-23 Downgrade
Jefferies
Buy → Hold
$14 → $1.50
Jan-27-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$23 → $3
Nov-09-22 Downgrade
Goldman
Buy → Neutral
$16 → $3
Mar-09-22 Initiated
Robert W. Baird
Outperform
$26
Mar-01-22 Initiated
Wells Fargo
Overweight
$25
Feb-18-22 Initiated
SMBC Nikko
Outperform
$25
Dec-16-21 Initiated
Guggenheim
Buy
$28
Jul-16-21 Initiated
Needham
Buy
$45
Jun-24-21 Initiated
Truist
Buy
$60
Jun-15-21 Initiated
BTIG Research
Buy
$44
Jun-09-21 Initiated
Wedbush
Outperform
$31
Jun-08-21 Initiated
JMP Securities
Mkt Outperform
$40
May-19-21 Initiated
Cantor Fitzgerald
Overweight
$44
May-11-21 Resumed
Jefferies
Buy
$34 → $45
Feb-24-21 Initiated
William Blair
Outperform
Jan-05-21 Initiated
Oppenheimer
Outperform
$42
Oct-19-20 Initiated
Morgan Stanley
Overweight
$29
Oct-19-20 Initiated
Jefferies
Buy
$34
Oct-19-20 Initiated
Goldman
Buy
$31
Show Previous Ratings
Today 10:01AM
08:00AM
Apr-29-24 01:37PM
Apr-15-24 05:30AM
(The Wall Street Journal) -9.52%
Apr-05-24 08:00AM
11:19AM
Loading…
Mar-20-24 11:19AM
08:01AM
(Thomson Reuters StreetEvents)
Mar-19-24 08:53PM
04:01PM
Mar-14-24 04:26PM
Mar-01-24 05:08PM
Feb-29-24 08:00AM
Feb-15-24 04:01PM
Feb-02-24 08:00AM
Jan-31-24 02:23PM
08:00AM
Loading…
Jan-22-24 08:00AM
Jan-15-24 09:30AM
Jan-10-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 07:30AM
Nov-29-23 08:00AM
Nov-15-23 02:00PM
12:52PM
(Thomson Reuters StreetEvents)
Nov-14-23 06:35PM
04:08PM
Nov-07-23 08:00AM
Oct-24-23 08:00AM
Oct-10-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 04:01PM
09:55AM
Loading…
Sep-05-23 09:55AM
Sep-04-23 03:04PM
Aug-24-23 08:00AM
Aug-15-23 01:54AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:02AM
07:00AM
Jul-31-23 08:00AM
Jul-18-23 07:08AM
Jun-28-23 08:00AM
Jun-15-23 08:00AM
Jun-05-23 08:00AM
May-19-23 12:54PM
08:00AM
May-16-23 11:41AM
May-12-23 10:15AM
(Thomson Reuters StreetEvents) -5.30%
May-11-23 04:01PM
May-04-23 08:00AM
Apr-27-23 04:52PM
Apr-15-23 08:24AM
Mar-30-23 06:08AM
Mar-28-23 04:01PM
Mar-15-23 04:01PM
Feb-14-23 05:32PM
(American City Business Journals)
Feb-08-23 05:42AM
Jan-31-23 04:01PM
Jan-24-23 02:32PM
(American City Business Journals)
Dec-19-22 02:05PM
(American City Business Journals) -9.35%
Dec-16-22 06:19PM
Dec-01-22 09:55AM
Nov-29-22 04:01PM
Nov-08-22 07:00AM
Nov-03-22 08:26PM
Nov-02-22 07:00AM
Oct-26-22 07:54PM
11:05AM
06:13AM
Oct-25-22 04:01PM
03:55PM
(American City Business Journals)
09:31AM
08:15AM
Oct-24-22 07:35PM
07:30PM
Oct-06-22 07:00AM
Aug-29-22 07:35AM
Aug-12-22 08:30AM
Aug-11-22 07:00AM
Aug-09-22 05:22PM
Aug-01-22 07:00AM
Jul-19-22 08:39AM
Jul-06-22 07:00AM
Jun-13-22 08:39AM
Jun-02-22 07:00AM
May-16-22 08:00PM
07:00AM
May-11-22 07:00AM
May-10-22 07:00AM
May-07-22 10:57AM
May-03-22 07:00AM
Apr-25-22 07:00AM
Apr-18-22 08:00AM
Apr-04-22 10:16AM
Mar-31-22 06:29PM
(American City Business Journals) +6.02%
05:30PM
01:31PM
07:00AM
Mar-29-22 07:00AM
Mar-24-22 07:00AM
Mar-23-22 07:00AM
Mar-16-22 11:14AM
Mar-08-22 07:00AM
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Manning Paul B 10% Owner Nov 17 '23 Buy 1.63 100,000 163,000 16,566,667 Nov 20 07:35 AM Alam Kamran Chief Financial Officer Aug 24 '23 Sale 2.33 33,000 76,890 258,042 Aug 25 04:30 PM Manning Paul B 10% Owner Aug 16 '23 Buy 0.90 16,466,667 14,820,000 16,466,667 Aug 16 08:57 PM Nolan Sean P. Chief Executive Officer Aug 16 '23 Buy 0.90 444,444 400,000 1,535,545 Aug 16 08:52 PM Stalfort John A III Director Aug 16 '23 Buy 0.90 388,889 350,000 884,290 Aug 16 08:53 PM Stalfort John A III Director Aug 16 '23 Buy 0.90 388,889 350,000 999,381 Aug 16 08:53 PM Donenberg Phillip B. Director Aug 16 '23 Buy 0.90 111,111 100,000 114,111 Aug 16 08:51 PM Session R.A. II 10% Owner Jul 13 '23 Sale 0.70 5,344 3,741 8,871,747 Jul 14 04:00 PM Session R.A. II 10% Owner Jul 12 '23 Sale 0.71 80,528 57,030 8,877,091 Jul 14 04:00 PM Session R.A. II 10% Owner Jun 23 '23 Sale 0.70 18,100 12,735 8,957,619 Jun 26 04:46 PM Session R.A. II 10% Owner Jun 22 '23 Sale 0.70 10,508 7,384 8,975,719 Jun 26 04:46 PM Session R.A. II 10% Owner Jun 21 '23 Sale 0.70 138,962 97,635 8,986,227 Jun 22 04:00 PM Session R.A. II 10% Owner Jun 20 '23 Sale 0.71 295,653 210,209 9,125,189 Jun 22 04:00 PM Nagendran Sukumar President and Head of R&D May 16 '23 Buy 0.68 5,000 3,400 34,226 May 18 04:44 PM
Index RUT
P/E -
EPS (ttm) -1.46
Insider Own 40.00%
Shs Outstand 42.41M
Perf Week -0.43%
Market Cap 280.87M
Forward P/E -
EPS next Y -0.75
Insider Trans 12.78%
Shs Float 25.45M
Perf Month 7.49%
Income -67.00M
PEG -
EPS next Q -0.45
Inst Own 42.47%
Short Float 15.07%
Perf Quarter 15.15%
Sales 5.12M
P/S 54.86
EPS this Y -2.53%
Inst Trans -9.35%
Short Ratio 26.34
Perf Half Y 79.92%
Book/sh 0.47
P/B 14.21
EPS next Y 50.82%
ROA -106.07%
Short Interest 3.84M
Perf Year 6.97%
Cash/sh 1.64
P/C 4.04
EPS next 5Y -
ROE -224.08%
52W Range 2.86 - 7.76
Perf YTD -9.55%
Dividend Est. -
P/FCF -
EPS past 5Y -0.97%
ROI -103.75%
52W High -14.62%
Beta 1.74
Dividend TTM -
Quick Ratio 4.49
Sales past 5Y -13.60%
Gross Margin 75.34%
52W Low 131.51%
ATR (14) 0.36
Dividend Ex-Date -
Current Ratio 4.55
EPS Y/Y TTM -78.42%
Oper. Margin -1233.82%
RSI (14) 51.34
Volatility 6.01% 5.54%
Employees 100
Debt/Eq 2.30
Sales Y/Y TTM -43.27%
Profit Margin -1307.47%
Recom 1.00
Target Price 13.67
Option/Short Yes / Yes
LT Debt/Eq 2.27
EPS Q/Q -268.07%
Payout -
Rel Volume 1.58
Prev Close 6.85
Sales Surprise 103.86%
EPS Surprise 5.69%
Sales Q/Q 2823.53%
Earnings Feb 29 BMO
Avg Volume 145.63K
Price 6.62
SMA20 -4.11%
SMA50 11.76%
SMA200 31.57%
Trades
Volume 105,363
Change -3.34%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-25-23 Upgrade
Needham
Hold → Buy
$10
Mar-22-23 Initiated
Jefferies
Buy
$10
Feb-13-23 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$4 → $11
May-25-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$16 → $4
May-14-21 Initiated
RBC Capital Mkts
Outperform
$19
Dec-24-20 Reiterated
H.C. Wainwright
Buy
$18 → $21
Jul-15-20 Downgrade
BofA Securities
Buy → Neutral
Jun-30-20 Reiterated
H.C. Wainwright
Buy
$24 → $18
Jun-24-20 Initiated
Northland Capital
Outperform
$21
Mar-24-20 Initiated
Needham
Buy
$20
Feb-21-19 Initiated
H.C. Wainwright
Buy
$20
Show Previous Ratings
Apr-27-24 06:00AM
Apr-02-24 07:30AM
Mar-26-24 07:30AM
Mar-01-24 09:10AM
Feb-29-24 08:11AM
07:30AM
Loading…
07:30AM
Feb-27-24 07:30AM
Feb-22-24 07:30AM
Feb-05-24 07:30AM
Jan-29-24 07:30AM
Jan-22-24 07:44PM
Jan-05-24 07:30AM
Jan-04-24 07:30AM
Jan-03-24 07:30AM
Dec-15-23 01:49PM
06:00AM
Loading…
06:00AM
Nov-11-23 10:13AM
Nov-10-23 08:00AM
Nov-09-23 07:30AM
Oct-25-23 07:00AM
Sep-27-23 08:00AM
Aug-31-23 08:00AM
Aug-24-23 08:30AM
Aug-23-23 07:30AM
Aug-10-23 04:05PM
Aug-08-23 07:30AM
Aug-03-23 07:30AM
Jul-27-23 06:06AM
Jul-26-23 04:05PM
Jul-25-23 07:16AM
03:16PM
Loading…
Jul-24-23 03:16PM
07:00AM
Jul-21-23 04:47PM
04:30PM
04:24PM
Jul-17-23 07:22AM
Jul-12-23 03:16AM
May-31-23 07:00AM
May-30-23 12:34PM
May-10-23 07:30AM
06:11AM
May-09-23 07:30AM
May-05-23 09:07AM
Apr-26-23 08:01PM
Apr-12-23 07:00AM
Apr-11-23 07:00AM
Mar-06-23 07:30AM
Feb-28-23 04:05PM
Feb-27-23 04:05PM
Feb-22-23 11:49AM
(American City Business Journals)
Feb-21-23 07:22AM
Feb-17-23 06:43PM
Feb-14-23 10:15AM
Jan-24-23 07:30AM
07:16AM
Jan-04-23 07:30AM
Jan-01-23 08:16AM
Dec-12-22 12:07PM
Nov-26-22 07:00AM
Nov-07-22 04:05PM
Aug-31-22 04:30PM
Aug-17-22 07:53AM
Aug-11-22 07:30AM
Aug-04-22 01:38PM
12:34PM
Aug-03-22 12:02PM
Aug-01-22 07:30AM
Jul-20-22 12:00PM
Jul-18-22 11:43AM
Jul-07-22 06:10AM
(Simply Wall St.) +10.62%
Jul-06-22 09:31AM
Jul-01-22 09:36AM
(American City Business Journals) +13.02%
Jun-29-22 09:23PM
04:01PM
03:26PM
Jun-28-22 07:30AM
Jun-17-22 09:35AM
Jun-13-22 09:55AM
Jun-05-22 08:42AM
Jun-01-22 09:35AM
May-26-22 03:37PM
May-25-22 03:14PM
08:18AM
06:39AM
May-24-22 09:12PM
08:00PM
May-17-22 11:53AM
May-16-22 09:35AM
May-13-22 09:35AM
May-11-22 06:35AM
May-09-22 07:30AM
Apr-08-22 12:15PM
(American City Business Journals)
Apr-07-22 07:30AM
Apr-05-22 07:30AM
Mar-06-22 06:45AM
Mar-02-22 04:05PM
Feb-24-22 07:30AM
Dec-17-21 05:23AM
Dec-15-21 04:05PM
Dec-08-21 05:01AM
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PERCEPTIVE ADVISORS LLC 10% Owner Dec 29 '23 Buy 7.24 115,774 838,204 7,099,182 Dec 29 05:27 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 28 '23 Buy 7.08 126,116 892,901 6,983,408 Dec 29 05:27 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 27 '23 Buy 7.20 79,726 574,027 6,857,292 Dec 29 05:27 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 26 '23 Buy 6.49 54,652 354,691 6,777,566 Dec 26 07:21 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 22 '23 Buy 6.67 250,000 1,667,500 6,722,914 Dec 26 07:21 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 21 '23 Buy 6.17 200,000 1,234,000 6,472,914 Dec 26 07:21 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 19 '23 Buy 5.36 277,008 1,484,763 6,272,914 Dec 19 05:52 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 18 '23 Buy 5.41 456,923 2,471,953 5,995,906 Dec 19 05:52 PM PERCEPTIVE ADVISORS LLC 10% Owner Dec 15 '23 Buy 5.97 500,000 2,985,000 5,538,983 Dec 19 05:52 PM Hayes Christopher G. Chief Legal Officer Nov 15 '23 Sale 2.97 11,558 34,327 123,226 Nov 16 04:32 PM White Ted President and CEO Nov 15 '23 Sale 2.97 11,558 34,327 170,090 Nov 16 04:33 PM Bonaccorso Joe Chief Commercial Officer Nov 15 '23 Sale 2.97 11,266 33,460 92,392 Nov 16 04:49 PM Kohler Terry Chief Financial Officer Nov 15 '23 Sale 2.97 9,632 28,607 34,416 Nov 16 04:34 PM Goldenberg Gary Chief Medical Officer Nov 15 '23 Sale 2.97 3,036 9,017 86,257 Nov 16 04:35 PM Hayes Christopher G. Chief Legal Officer Nov 14 '23 Sale 2.93 22,141 64,873 134,784 Nov 16 04:32 PM White Ted President and CEO Nov 14 '23 Sale 2.93 22,141 64,873 181,648 Nov 16 04:33 PM Bonaccorso Joe Chief Commercial Officer Nov 14 '23 Sale 2.93 21,580 63,229 103,658 Nov 16 04:49 PM Kohler Terry Chief Financial Officer Nov 14 '23 Sale 2.93 18,452 54,064 44,048 Nov 16 04:34 PM Goldenberg Gary Chief Medical Officer Nov 14 '23 Sale 2.93 5,817 17,044 89,293 Nov 16 04:35 PM Manning Paul B Director Jul 24 '23 Buy 5.02 200,000 1,004,000 7,851,128 Jul 24 06:47 PM White Ted President and CEO Jul 24 '23 Sale 4.83 50,677 244,770 128,789 Jul 25 04:18 PM Bonaccorso Joe Chief Commercial Officer Jul 24 '23 Sale 4.83 38,262 184,805 62,738 Jul 25 04:22 PM Hayes Christopher G. Chief Legal Officer Jul 24 '23 Sale 4.83 33,789 163,201 81,925 Jul 25 04:25 PM Goldenberg Gary Chief Medical Officer Jul 24 '23 Sale 4.83 28,699 138,616 70,110 Jul 25 04:23 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite